Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Marsh

Neurology with Special Qualifications in Child Neurology Philadelphia, PA Medical Doctor

NPI 1821012204 CMS profile 614268

3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Neurology, Philadelphia, PA 19104

Open in the dashboard

General payments

$27,538

42 records reported · program years 2019–2025

Research payments

$27,712

Paid to them · 28 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,877,390 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Eric Marsh of Philadelphia, PA is reported in the CMS Open Payments database as having received $27,538 across 42 general payments and $27,712 in research payments paid to them. Separately, studies naming them as principal investigator received $1,877,390 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,570 30
2025 Research $23,120 3
2024 General $693 1
2023 General $136 1
2022 General $2,700 2
2019 General $3,439 8
2019 Research $4,592 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Marsh
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Eric Marsh were reported at $20,570. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Eric Marsh Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $3,439 $262 $68–$1,313 $163
2020 $0 $188 $46–$1,222 $114
2021 $0 $183 $45–$1,356 $132
2022 $2,700 $229 $72–$1,177 $149
2023 $136 $269 $93–$1,195 $160
2024 $693 $300 $98–$1,428 $164
2025 $20,570 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $16,497 15 payments
  2. UCB, Inc. $3,060 3 payments
  3. Jazz Pharmaceuticals Inc. $2,420 4 payments
  4. Cipla USA Inc. $2,000 1 payment
  5. GW Research Limited $1,439 7 payments
  6. Ionis Pharmaceuticals, Inc. $1,429 11 payments
  7. EMD Serono, Inc. $693 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $16,874 10 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,150 2 payments
  3. Travel and Lodging $3,111 12 payments
  4. Food and Beverage $1,383 17 payments
  5. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. DAYBUE $13,797 13 payments
  2. Fintepla $3,060 3 payments
  3. Epidiolex $2,420 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ucb SA $23,120 3 payments
  2. ACADIA Pharmaceuticals Inc $4,592 25 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

104

Median for Neurology: 833

Drug cost

$1,721,325

Median for Neurology: $202,670

Branded share of claims

74%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Daybue Trofinetide Brand 23 $1,575,866
Epidiolex Cannabidiol (Cbd) Brand 26 $96,687
Briviact Brivaracetam Brand 16 $26,218
Onfi Clobazam Brand 12 $21,417
Zonisamide Generic 15 $1,059
Clonazepam Generic 12 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record